Jun. 29 at 5:51 PM
$KZIA Nobody would question an immediate NPV of one billion dollars, for a standout positive meeting TYPE C meet with the FDA soon. That represents a 600% SP gap. This is a highly impactful situation, completely not understand by the market. Significant and highly relevant news from the last week or do. A must to google for more detail. The FDA dramatically reversed its stance on AMT-130, an experimental gene therapy by UniQure that slows Huntington's disease progression. After initially demanding a new trial, the FDA agreed to accept existing three-year data to support an application for accelerated approval in the U.S.This sudden U-turn means the regulatory process is back on track. Accelerated approval is now likely to be forthcoming from the FDA, in this rare brain disease.
